Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically regarding the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details the following share transactions executed on behalf of employee investment plan participants:
- February 13, 2006: 820 Ordinary shares sold at GBP 14.96 per share for a participant in the SmithKline Beecham Bonus Investment Plan. Additionally, 1,178 Ordinary shares were transferred from the Trust to a participant in the same plan.
- February 15, 2006: 1,820 Ordinary shares sold at GBP 14.67 per share for a participant in the GlaxoSmithKline Annual Investment Plan. Additionally, 2,562 Ordinary shares were transferred from the Trust to a participant in the same plan.
Director Mr. J Heslop is noted as having an interest in the shares held in the Trust, consistent with other non-US employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of the aforementioned share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares sold and transferred by the SmithKline Beecham Employee Benefit Trust during the reporting period.
- Confirm the transaction prices of GBP 14.96 and GBP 14.67 against market data for February 13 and 15, 2006.
- Note that Director Mr. J Heslop holds an indirect interest in the Trust's holdings.
- Recognize that this filing contains no financial performance data for the company.